Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the safety and efficacy of CC-95251, a novel monoclonal antibody targeting SIRPα, for the treatment of relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Dr Strati first explains the advantages of targeting SIRPα, and then goes on to discuss the interim results of a trial evaluating the safety and efficacy of this agent in combination with rituximab for patients with R/R NHL (NCT03783403). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.